ANTH Anthera Pharmaceuticals Inc

USD 0.00 0.00 0
Icon

Anthera Pharmaceuticals Inc (ANTH) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.00

0.00 (0.00)%

USD 6.18K

N/A

N/A

N/A

Icon

ANTH

Anthera Pharmaceuticals Inc (USD)
COMMON STOCK | OTC
USD 0.00
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 6.18K

N/A

USD 0.00

Anthera Pharmaceuticals Inc (ANTH) Stock Forecast

N/A

Based on the Anthera Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Anthera Pharmaceuticals Inc is not available over the next 12 months. Anthera Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Anthera Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Anthera Pharmaceuticals Inc’s stock price was USD 0.00. Anthera Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Anthera Pharmaceuticals Inc
No recent average analyst rating found for Anthera Pharmaceuticals Inc

Company Overview Anthera Pharmaceuticals Inc

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical...Read More

https://www.anthera.com

The Pennzoil Building, Houston, TX, United States, 77002

21

December

USD

USA

Adjusted Closing Price for Anthera Pharmaceuticals Inc (ANTH)

Loading...

Unadjusted Closing Price for Anthera Pharmaceuticals Inc (ANTH)

Loading...

Share Trading Volume for Anthera Pharmaceuticals Inc Shares

Loading...

Compare Performance of Anthera Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ANTH

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Anthera Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S 0.00 (0.00%) USD456.53B 41.43 4.67

ETFs Containing ANTH

Symbol Name ANTH's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Anthera Pharmaceuticals Inc (ANTH) Stock

Stock Target Advisor's fundamental analysis for Anthera Pharmaceuticals Inc's stock is Bearish.

Unfortunately we do not have enough data on ANTH's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ANTH's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ANTH's stock to indicate if its overvalued.

The last closing price of ANTH's stock was USD 0.00.

The most recent market capitalization for ANTH is USD 6.18K.

Unfortunately we do not have enough analyst data on ANTH's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Anthera Pharmaceuticals Inc's stock.

As per our most recent records Anthera Pharmaceuticals Inc has 21 Employees.

Anthera Pharmaceuticals Inc's registered address is The Pennzoil Building, Houston, TX, United States, 77002. You can get more information about it from Anthera Pharmaceuticals Inc's website at https://www.anthera.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...